Syros Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Syros Pharmaceuticals şirketinin toplam hissedar öz sermayesi $-11.1M ve toplam borcu $41.1M olup, bu da borç-öz sermaye oranını -369.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $85.0M ve $96.1M dir.

Anahtar bilgiler

-369.3%

Borç/özkaynak oranı

US$41.08m

Borç

Faiz karşılama oranı	n/a
Nakit	US$58.28m
Eşitlik	-US$11.12m
Toplam yükümlülükler	US$96.12m
Toplam varlıklar	US$85.00m

Son finansal sağlık güncellemeleri

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SYRS negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: SYRS şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SYRS negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: SYRS 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SYRS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: SYRS un, serbest nakit akışı her yıl % 15.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Syros Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought US$161k worth of stock

Price target decreased by 56% to US$8.75

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

New major risk - Financial position

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Scientific Founder notifies of intention to sell stock

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%

Price target decreased to US$14.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Syros Pharmaceuticals Is A Buy As New Trials Start

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway